Navigation Links
Accipiter Life Sciences Announces Nomination of Three Independent Director Candidates for Election to the Penwest Board at the 2008 Annual Meeting
Date:2/15/2008

NEW YORK, Feb. 15 /PRNewswire/ -- Accipiter Life Sciences Fund, LP ("Accipiter Life Sciences"), announced today that it has nominated Gabe Hoffman, David Lohman and Eugene I. Davis for election to the Board of Directors of Penwest Pharmaceuticals Co. (the "Company") (Nasdaq: PPCO) at the Company's 2008 Annual Meeting of Shareholders. The Company has not announced the date of the annual meeting. Accipiter Life Sciences, which, together with its affiliates, beneficially owns 2,168,213 shares, or approximately 9.3% of the outstanding shares, of common stock of the Company, submitted written notice of the nominations to the Company's Corporate Secretary in a letter dated February 15, 2008.

CERTAIN INFORMATION CONCERNING PARTICIPANTS

Accipiter Life Sciences Fund, LP ("Accipiter Life Sciences"), together with the other Participants (as defined below), intend to make a preliminary filing with the Securities and Exchange Commission ("SEC") of a proxy statement and accompanying proxy card to be used to solicit votes for the election of a slate of director nominees at the 2008 annual meeting of shareholders of Penwest Pharmaceuticals Co., a Washington corporation (the "Company").

ACCIPITER LIFE SCIENCES ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT WHEN IT IS AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY STATEMENT WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THE SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR.

The participants in the proxy solicitation are anticipated to be Accipiter Life Sciences Fund (Offshore), Ltd., ("ALS Fund Offshore"), Accipiter Life Sciences Fund II, LP, ("ALS Fund II"), Accipiter Life Sciences Fund II (Offshore), Ltd., ("ALS Fund II Offshore"), Accipiter Life Sciences Fund II (QP), LP, ("ALS Fund II QP") (together with Accipiter Life Sciences, ALS Fund Offshore, ALS Fund II, ALS Fund II Offshore, ALS Fund II QP, the "Accipiter Entities"), Accipiter Capital Management, LLC, ("Accipiter Management"), Candens Capital, LLC, ("Candens Capital"), Gabe Hoffman, David Lohman and Eugene I. Davis. As of the date of this filing, Accipiter Life Sciences, ALS Fund II and ALS Fund II QP beneficially owned 555,745, 254,029 and 290,330 shares of Common Stock of the Company, respectively. As the general partner of each of Accipiter Life Sciences, ALS Fund II and ALS Fund II QP, Candens Capital may be deemed to beneficially own the 1,100,104 shares of Common Stock of the Company collectively owned by Accipiter Life Sciences, ALS Fund II and ALS Fund II QP.

As of the date of this filing, ALS Fund Offshore and ALS Fund II Offshore beneficially owned 557,048 and 511,061 shares of Common Stock of the Company, respectively. As the investment manager of each of ALS Fund Offshore and ALS Fund II Offshore, Accipiter Management may be deemed to beneficially own the 1,068,109 shares of Common Stock of the Company collectively owned by ALS Fund Offshore and ALS Fund II Offshore.

As of the date of this filing Mr. Hoffman may be deemed to beneficially own 2,168,213 shares of Common Stock collectively owned by the Accipiter Entities. Mr. Hoffman has sole voting and dispositive power with respect to the 2,168,213 Shares owned by the Accipiter Entities. Each of Candens Capital, Accipiter Management and Gabe Hoffman disclaims beneficial ownership of the shares of Common Stock of the Company owned by the Accipiter Entities except to the extent of its or his pecuniary interest therein. Currently, each of Messrs. Lohman and Davis do not beneficially own any shares of Common Stock of the Company. As members of a "group" for the purposes of Rule 13d-5(b)(1) of the Securities Exchange Act of 1934, as amended, each of Messrs. Lohman and Davis are deemed to beneficially own the 2,168,213 shares of Common Stock owned by the Accipiter Entities.


'/>"/>
SOURCE Accipiter Life Sciences Fund, LP
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
2. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
3. Rural/Metro Board of Directors Meets With Accipiter Capital Management
4. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
5. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
6. Pennsylvania Gov. Rendell: $10 Million Partnership With Harrisburg Venture Capital Firm Boosts PAs Life Sciences Industry
7. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
8. Edwards Lifesciences Reports Strong Fourth Quarter Sales
9. 7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton
10. Advanced Life Sciences to Participate in Antibiotics Expert Panel at the 10th Annual BIO CEO & Investor Conference
11. Caliper Life Sciences Ships 500th IVIS Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease ... end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the end ... mandated by certain health insurance regulations. ... The best time to get a flu shot is by the end ...
Breaking Medicine Technology: